Bright minds at Vanderbilt University have unveiled a breakthrough technology that could bring sophisticated biomarker diagnostics to the developing world. The point-of-care diagnostic is designed to be used in the field; no specialized equipment, expertise, or white lab coats are required. The diagnostic is based upon the ingenous observation that evaporating liquid droplets leave behind a characteristic ring pattern, which may be familiar to our readers in the form of a coffee-ring stain.
The OLINDA/EXM® personal computer code performs dose calculations and kinetic modeling for radiopharmaceuticals (OLINDA/EXM stands for Organ Level INternal Dose Assessment/EXponential Modeling). OLINDA® calculates radiation doses to different organs of the body from systemically administered radiopharmaceuticals and performs regression analysis on user-supplied biokinetic data to support such calculations for nuclear medicine drugs. These calculations are used to perform risk/benefit evaluations of the use of such pharmaceuticals in diagnostic and therapeutic applications in nuclear medicine. The technology employs a number of standard body models for adults, children, pregnant women and others, that are widely accepted and used in the internal dose community. The calculations are useful to pharmaceutical industry developers, nuclear medicine professionals, educators, regulators, researchers and others who study the accepted radiation doses that should be delivered when radioactive drugs are given to patients or research subjects.
Heart valve disease is the 3rd most prevalent source of cardiovascular disease, leading to approximately 20,000 deaths per year in the U.S. alone. Moreover, there are an estimated 41,000 mitral valve procedures performed in the U.S. each year. The only effective, long-term treatment for mitral valve disease is open-chest valve replacement surgery, which is highly undesirable for elderly patients. Thus, there is a pressing need to develop novel percutaneous strategies for treatment that will reduce the number of open-chest surgeries. David Merryman and colleagues have developed a new, combined catheter that uses cryo temperatures to adhere to moving mitral valve leaflets and radiofrequency ablation to alter the compliance of the leaflet tissue to prevent prolapse and regurgitation.
This technology enables the delivery of biological molecules into the interior of a cell. Such a delivery mechanism could be utilized in a variety of therapies including peptide, gene transfer and/or antisense therapy.
This invention relates generally to a method of identifying an individual having an increased susceptibility to developing Familial Primary Pulmonary Hypertension (FPPH), as well as to a method for diagnosing an individual suffering from FPPH. The invention also relates to a method of identifying an individual having an increased susceptibility to developing (non-familial) Primary Pulmonary Hypertension (PPH), as well as to a method for diagnosing an individual suffering from PPH.
This technology facilitates the discovery and design of novel agents for either repelling or otherwise controlling insects that have important economic or medical significance. In particular, mosquitoes are responsible for transmitting a number of diseases, including malaria, West Nile, dengue and yellow fevers. The Zwiebel laboratory has identified human odorants and the protein receptors in mosquitoes that allow female mosquitoes to identify their hosts when they need blood to satisfy their reproductive needs. With funding from the Gates Foundation's Grand Challenge in Global Health initiative, the Zwiebel laboratory, along with collaborators at Yale, Wageningen University in the Netherlands, and researchers in Africa, developed biological and behavioral assays to screen and test numerous agents as potential repellants and attractants for the Anopholes gambiae mosquito. These methods have been applied to include agricultural pests, disease vectors and nuisance insects (important for many tourist-based economies).
Phosphodiesterase-5 (PDE5) is an enzyme which degrades cyclic guanosine monophosphate (cGMP) in smooth muscle cells. The common known drug Viagra is similar in molecular structure to cGMP and acts as a competitive binding agent of PDE5. Thus in the presence of Viagra unbound cGMP levels increase which results in smooth muscle relaxation or vasodilation leading to an increased inflow of blood. Vanderbilt researchers have developed a method for assaying compounds which bind PDEs. Not only will this method be useful in identify other PDE inhibitors but due to the high affinity of this system this method could be used to identify and isolate PDEs from various crude tissue fractions.
Isolated and purified lipoxygenase proteins and nucleic acids are described. Particularly, a novel human 15(S) lipoxygenase (15-Lox-2) protein and cDNA and a cDNA for mouse 8S-lipoxygenase are described. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also described, along with methods of producing each. Isolated and purified antibodies to 15-Lox-2 and 8-Lox, and methods of producing the same, are also described.
This invention relates to fatty acid 13-hydroperoxide lyase protein from guava (Psidium guajava) and the gene encoding the protein. Expression systems for recombinant guava 13-hydroperoxide lyase and methods of using recombinant guava 13-hydroperoxide lyase for the production of green notes are provided.
An isolated nucleic acid encoding the Helicobacter pylori recombinase comprising the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. Also provided is an isolated nucleic acid that selectively hybridizes with the nucleic acid of claim 1 under stringent conditions and has at least 70% complementarity with the segment of the nucleic acid of SEQ ID NO:1 to which it hybridizes. Also provided is a mutant strain of H. pylori that does not express a functional recombinase (recA.sup.- mutant). An immunogenic amount of the recA.sup.- mutant H. pylori in a pharmaceutically acceptable carrier is provided. A method of immunizing a subject against infection by H. pylori comprises administering to the subject an immunogenic amount of mutant H. pylori in a carrier for the mutant.
The technology provides a method for diagnosis of MS by detection of Chlamydia and treatment of MS by total eradication of Chlamydia. This technology provides for eradication of Chlamydia by a novel treatment of combining various anti-chlamydial agents directed at different phases of the chlamydial life cycle.